Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Qing Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2182-5709; OpenAlex author ID A5100765965, A5128277481. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 17)
Trials
0
Grants
0
Labs led
2
Collaborators
30
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 4 papers · 2024: 4 papers · 2025: none · 2026: 4 papers

Papers 22

  1. circPLEKHM1 promotes tumor growth and metastasis through enhancing FXR1-mediated protein translation in PDAC. Last author DOI 10.1016/j.canlet.2026.218414↗
  2. Pan-cancer analysis identifies GPRIN1 as a prognostic biomarker and promoter of cell proliferation in pancreatic cancer. Last author DOI 10.1016/j.yexmp.2026.105061↗
  3. Agrimol B inhibits pancreatic ductal adenocarcinoma by induction of lethal mitophagy through decreasing mitochondrial transcription termination factor 3. Last author DOI 10.1093/pcmedi/pbag009↗
  4. Serum SAMD9 as a Potential Prognostic Biomarker for Pancreatic Cancer. Last author DOI 10.3390/cancers18172781↗
  5. tiRNA-Val-CAC-2 interacts with FUBP1 to promote pancreatic cancer metastasis by activating c‑MYC transcription. Last author DOI 10.1038/s41388-024-02991-9↗
  6. Osthole induces accumulation of impaired autophagosome against pancreatic cancer cells. Co-author DOI 10.1038/s41598-024-81911-z↗
  7. Establishment and Verification of a Novel Gene Signature Connecting Hypoxia and Lactylation for Predicting Prognosis and Immunotherapy of Pancreatic Ductal Ade… Last author DOI 10.3390/ijms252011143↗
  8. Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. Last author DOI 10.7717/peerj.18018↗
  9. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer. Last author DOI 10.1002/cam4.5774↗
  10. Histone Modifications Represent a Key Epigenetic Feature of Epithelial-to-Mesenchyme Transition in Pancreatic Cancer. First author DOI 10.3390/ijms24054820↗
  11. The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma. Last author DOI 10.3390/jcm12041398↗
  12. Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment. Co-author DOI 10.3390/pharmaceutics15102421↗
  13. Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.apsb.2022.01.018↗
  14. Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/jcm11113101↗
  15. Krüppel-like Factor 6 Suppresses the Progression of Pancreatic Cancer by Upregulating Activating Transcription Factor 3. Last author DOI 10.3390/jcm12010200↗
  16. Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Among Kinesin Superfamily of Proteins in Pancreatic Ductal Aden… Last author DOI 10.3389/fonc.2021.708900↗
  17. ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma. Last author DOI 10.1097/md.0000000000019413↗
  18. Evaluation of the target genes of arsenic trioxide in pancreatic cancer by bioinformatics analysis. Co-author DOI 10.3892/ol.2019.10889↗
  19. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.1833↗
  20. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. Last author DOI 10.18632/oncotarget.4529↗
  21. The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy. Last author DOI 10.1155/2014/268479↗
  22. Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer. Last author DOI 10.1111/j.1365-3083.2011.02657.x↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qunli Xiong · 9 shared papers, 2021–2026 · strength 1.80
  2. Ningna Weng · 8 shared papers, 2019–2026 · strength 1.57
  3. Yongfeng Xu · 7 shared papers, 2021–2024 · strength 1.27
  4. Jinlu Liu · 5 shared papers, 2022–2026 · strength 1.07
  5. Zhiwei Zhang · 5 shared papers, 2022–2024 · strength 0.96
  6. Ying Zheng · 4 shared papers, 2022–2026 · strength 0.93
  7. XunJie Cao · 2 shared papers, 2026 · strength 0.79
  8. Congya Zhou · 5 shared papers, 2015–2023 · strength 0.50
  9. Ying Xin Xu · 1 shared paper, 2023 · strength 0.39
  10. Zhu Zeng · 2 shared papers, 2023–2024 · strength 0.36
  11. Xingyu He · 1 shared paper, 2026 · strength 0.36
  12. Suxia Han · 5 shared papers, 2012–2022 · strength 0.34
  13. Yifei Ma · 1 shared paper, 2026 · strength 0.32
  14. Hong Zhu · 1 shared paper, 2023 · strength 0.26
  15. Ying Cao Xu · 1 shared paper, 2024 · strength 0.26
  16. Y. Yang · 1 shared paper, 2026 · strength 0.25
  17. Yong Peng · 1 shared paper, 2026 · strength 0.25
  18. Xiaojuan Yang · 1 shared paper, 2026 · strength 0.25
  19. Sha Huang · 1 shared paper, 2024 · strength 0.23
  20. Yang Yang · 1 shared paper, 2023 · strength 0.18
  21. Xing Huang · 1 shared paper, 2022 · strength 0.13
  22. Zhe Zhang · 1 shared paper, 2022 · strength 0.13
  23. Canhua Huang · 1 shared paper, 2022 · strength 0.13
  24. Ajay Goel · 1 shared paper, 2022 · strength 0.13
  25. Yang Yang · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.